Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TCX 001

Next Previous
Drug Profile

TCX 001

Alternative Names: TCX-001

Latest Information Update: 16 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Wuerzburg
  • Developer T-CURX
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Chronic lymphocytic leukaemia

Most Recent Events

  • 11 Jun 2026 T-CURX announces intention to submit CTIS application to European Medicines Agency (EMA) for extending the phase I trial in Acute myeloid leukemia and Chronic lymphocytic leukemia to four sites in Germany
  • 11 Jun 2026 The Swissmedic approves a clinical trial for TCX 001 in to Acute myeloid leukemia and Chronic lymphocytic leukemia
  • 11 Jun 2026 T-CURX plans a phase I trial for Acute myeloid leukemia (Second-line therapy or greater) and Chronic lymphocytic leukemia in Switzerland and Germany

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top